Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises

Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 gene. It comprises approximately 15-20% of breast cancers (BCs). Unfortunately, TNBC’s treatment continues to be a clinical problem because of its relatively poor prognosis, its aggre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Genomics Proteomics
Autores principales: GARMPIS, NIKOLAOS, CHRISTOS, DAMASKOS, GARMPI, ANNA, KALAMPOKAS, EMMANOUIL, KALAMPOKAS, THEODOROS, SPARTALIS, ELEFTHERIOS, DASKALOPOULOU, AFRODITE, VALSAMI, SERENA, KONTOS, MICHAEL, NONNI, AFRODITI, KONTZOGLOU, KONSTANTINOS, PERREA, DESPINA, NIKITEAS, NIKOLAOS, DIMITROULIS, DIMITRIOS
Formato: Artigo
Lenguaje:Inglês
Publicado: International Institute of Anticancer Research 2017
Materias:
Review Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5611517/
https://ncbi.nlm.nih.gov/pubmed/28870998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/cgp.20041
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares